Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Hepatitis C, HIV-1-infection, Liver Diseases
Interventions: Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy; Drug · Other
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Hepatitis C
Interventions: Simeprevir, Sofosbuvir, Ribavirin; Drug
Lead sponsor: SC Liver Research Consortium, LLC; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: La Jolla, California • New York, New York • Murray, Utah

Conditions: Hepatitis C, Lung Transplant
Interventions: Epclusa; Drug
Lead sponsor: Pablo Sanchez; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: PT-NANBH
Interventions: Simeprevir, Sofosbuvir; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 72 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Palo Alto, California • New Haven, Connecticut

Conditions: Hepatitis C Virus, Liver Transplantation
Interventions: Not listed
Lead sponsor: Schiano, Thomas D., MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Immunodeficiency Virus, Hepatitis C
Interventions: EBR/GZR; Drug
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 40 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatitis C, Hepatitis C, Chronic
Interventions: thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 46
States / cities: Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more

Conditions: HIV, Hepatitis C, Hepatitis B, Syphilis
Interventions: Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only; Device
Lead sponsor: California State University, Long Beach; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Chronic Hepatitis C, Genotype 1, Relapse
Interventions: Betaine, Peginterferon alpha 2a, Ribavirin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hepatocellular Carcinoma, HCC, Hepatitis C, HCV
Interventions: Automated reminders, Patient navigation; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: Peg-Intron, REBETOL, HCV 796; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Anaheim, California • La Jolla, California • Los Angeles, California + 26 more

Conditions: Respiratory Failure, Hepatitis C
Interventions: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Virus Infection
Interventions: VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 31
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more

Conditions: Liver Cirrhosis, Chronic Hepatitis C
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: David E. Kaplan, MD MSc; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections, Hepatitis C
Interventions: Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Hepatitis C, Hepatitis C, Chronic
Interventions: Eligibility Screening, HCV test; Other · Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 72 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C
Interventions: GS-9669 tablets, Placebo to Match GS-9669 tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Hepatitis C
Interventions: ascorbic acid (vitamin C); Dietary Supplement
Lead sponsor: Health Innovations, Frontier Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hepatitis C
Interventions: N-acetylcysteine(Mucomyst); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Complication of Transplanted Liver, Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Search by objective public record fields.

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

SMV + SOF With/Without RBV for IFN-II Patients With CHC

Expanding the Pool in Lung Transplantation

Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation

Impact of Hepatitis C Therapy and Bone Health

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Behavioral Science Aspects of Rapid Test Acceptance

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C Virus (HCV) Treatment Completion or Withdrawal

A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C

Mucomyst for Hepatitis C

C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study

Prediction of Hepatitis C Recurrence in Liver Transplant Recipients

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072